NCT06828757View on ClinicalTrials.gov

Clinical Study of Nanocrystalline Megestrol in Malnourished Patients With First-Line Non-Small Cell Lung Cancer

PHASE3Not yet recruitingINTERVENTIONAL
Enrollment

94

Participants

Timeline

Start Date

May 1, 2025

Primary Completion Date

December 31, 2026

Study Completion Date

April 30, 2027

Conditions
Non Small Cell Lung Cancer
Interventions
DRUG

nanocrystalline megestrol oral suspension + PD-1/L1 inhibitor combined with chemotherapy

Oral suspension of nanocrystalline megestrol is taken orally once a day until disease progression or 12 weeks (maximum duration of 12 weeks) PD-1/L1 inhibitors combined with chemotherapy are given every 3 weeks for one dosing cycle.

DRUG

PD-1/L1 inhibitor combined with chemotherapy

PD-1/L1 inhibitors combined with chemotherapy are given every 3 weeks for one dosing cycle.

Trial Locations (1)

410013

Yongchang Zhang, Changsha

All Listed Sponsors
lead

Hunan Province Tumor Hospital

OTHER